HLB Co., Ltd. (KOSDAQ:028300)
South Korea
· Delayed Price · Currency is KRW 62,900
0.00 (0.00%)
Apr 29, 2026, 12:20 PM KST
HLB Co., Ltd. Revenue
In the year 2025, HLB Co., Ltd. had annual revenue of 84.17B KRW with 23.55% growth. HLB Co., Ltd. had revenue of 28.66B in the quarter ending December 31, 2025, with 13.64% growth.
Revenue
84.17B
Revenue Growth
+23.55%
P/S Ratio
99.31
Revenue / Employee
550.15M
Employees
153
Market Cap
8,359.56B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 84.17B | 16.05B | 23.55% |
| Dec 31, 2024 | 68.13B | 25.23B | 58.80% |
| Dec 31, 2023 | 42.90B | -136.81B | -76.13% |
| Dec 31, 2022 | 179.71B | 109.88B | 157.37% |
| Dec 31, 2021 | 69.83B | 13.65B | 24.30% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SK Biopharmaceuticals | 706.74B |
| LigaChem Biosciences | 141.55B |
| Peptron | 5.63B |
| Voronoi | 7.51B |
| Samsung Epis Holdings | 1,510.14B |
| OliX Pharmaceuticals | 14.67B |
| D&D Pharmatech | 4.30B |
| SK bioscience | 651.37B |